Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-22
2008-01-22
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S563000, C514S564000
Reexamination Certificate
active
07320988
ABSTRACT:
This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALEs) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs.
REFERENCES:
patent: 4661579 (1987-04-01), Blocker
patent: 4880794 (1989-11-01), Halskov
patent: 5093367 (1992-03-01), Lalezari et al.
patent: 5268500 (1993-12-01), Lalezari et al.
patent: 5272176 (1993-12-01), Ulrich et al.
patent: 5292935 (1994-03-01), Lalezari et al.
patent: 5602277 (1997-02-01), Babu et al.
patent: 5661139 (1997-08-01), Lankin et al.
patent: 5667330 (1997-09-01), Henkel et al.
patent: 5700447 (1997-12-01), Bucala et al.
patent: 5716987 (1998-02-01), Wille
patent: 5921997 (1999-07-01), Fogelberg et al.
patent: 5962651 (1999-10-01), Lalezari et al.
patent: 6337350 (2002-01-01), Rahbar et al.
patent: 6589944 (2003-07-01), Rahbar
patent: 6605642 (2003-08-01), Rahbar et al.
patent: 2002/0002203 (2002-01-01), Rahbar
patent: 2002/0013256 (2002-01-01), Rahbar et al.
patent: 2002/0128278 (2002-09-01), Rahbar et al.
patent: 2002/2123501 (2002-09-01), Rahbar et al.
patent: WO 92/07560 (1992-05-01), None
patent: WO 95/31192 (1995-11-01), None
patent: WO 98/55121 (1998-12-01), None
patent: WO 00/59875 (2000-10-01), None
patent: WO 00/66102 (2000-11-01), None
patent: WO 01/76584 (2001-10-01), None
patent: WO 02/072083 (2002-09-01), None
patent: WO 02/076443 (2003-10-01), None
patent: WO 04/071416 (2004-11-01), None
Medline Abstract No. 97217050, Kumar, Indian Journal of Experimental Biology, (May 1996) 34(5), 391-402.
Medline Abstract No. 96432582, Oka et al., Japanese Journal of Pharmacology (Jun. 1996) 71(2), 89-100.
Medline Abstract No. 97074593, Smith et al., CA: A Cancer Journal for Clinicans, (Nov.-Dec. 1996), 46(6), 343-63.
Medline Abstract No. 1998029329, Rickels et al., Journal of Clinical Psychiatry, (1997) 58 Suppl. 11, 4-10.
Al-Abed et al., “Advanced glycation end products: detection and reversal,”Methods Enzymol., 1999; 309:152-172.
Alderson et al., “The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats,”Kidney Int., 2003; 63:2123-2133.
Aldrich Catalog 805,786,8, and 3, 1994-1995.
Altomare et al., “Increased lipid peroxidation in type 2 poorly controlled diabetic patients,”Diabetes Metab., 1992; 18:264-271.
Anderson et al., “The myeloperoxidase system of human phagocytes generates N-epsilon (carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation,”J. Clin. Invest.,1999; 104:103-113.
Basta et al., “Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses,”Circulation, 2002; 105:816-822.
Baynes et al., “Perspective in diabetes: role of oxidative stress in diabetic complications. A new perspective on an old paradigm,”Diabetes,1999, 48:1-9.
Baynes et al., “Glycoxidation and lipoxidation in atherogenesis,”Free Rad. Biol. Med., 2000; 28:1708-1716.
Boulanger et al., “AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression,”Kidney Int., 2002; 61:148-156.
Brownlee, M., “Biochemistry and molecular cell biology of diabetic complications,”Nature, 2001; 414:813-820.
Bucala et al., “Advanced glycosylation: chemistry, biology and implications for diabetes and aging,”Adv. Pharmacol, 1992; 23:1-33.
Bucala et al., “Lipid and lipoprotein modification by advanced glycation end-products: Role in atherosclerosis,”Exper. Physiol., 1997; 82:327-337.
Bucala et al., “Lipid advanced glycation pathway for lipid oxidation in vivo,”Proc. Natl. Acad. Sci. USA; 1993; 90:6434-6438.
Bucala et al., “Protein glycation and vascular disease. In: Endocrinology of cardiovascular function,”E.R. Levin and J.L. Nadler(eds.). (1998) Kluwer Acad. Publishers, pp. 159-180.
Bucala et al., “Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression,”Proc. Natl. Acad Sci.USA, 1984; 81: 105-109.
Calatayud, J.M., “Favorable Effects of the Lipid-Lowering and Platelet Antiaggregant Plafibride on the Againg Process of Mice of the C57BL/6J Strain,”Math and Find Exptl Clin Pharmacol.,1983; 5(10):707-714.
Carew et al., “Antiatherogenic effect of probucol unrelated to its hypochloesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,”Proc. Natl. Acad. Sci. USA, 1987; 84:7725-7729.
Carpenter et al., “Oral α-tocopherol supplementation inhibits lipid oxidation in established human athersoclerotic lesions,”Free Radic. Res., 2003; 37:1235-1244.
Chaturvedi et al., “Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold,”Kidney Int.,2001; 60:219-227.
Chellen et al., “Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes,”Arch. Biochem. Biophys.,1999; 368:98-104.
Degenhardt et al., “Puridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat,”Kidney Int., 2002; 61:939-950.
Forbes et al., “Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy,”Diabetes, 2002; 51:3274-3282.
Friedman, “Advanced glycation end-products in diabetic nephropathy,”Nephrol. Dial. Transplant., 1999; 14(Suppl 3):1-9.
Fu et al., “The advanced glycation end product, Nε-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions,”J. Biol. Chem.,1996; 271:9982-9986.
Gogas Yavuz et al., “Effects of aminoguanidine on lipid and protein oxidation in diabetic rat kidneys,”Int. J. Exp. Diabetes Res., 2002; 3:145-151.
Hedrick et al., “Glycation impairs high-density lipoprotein function,”Diabetologia, 2000; 43:312-320.
Heinecke, “Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis,”Atherosclerosis, 1998; 141:1-15.
Hicks et al., “Catalysis of lipid peroxidation by glucose and glycosylated collagen,”Biochem. Biophys. Res. Commun.,1988; 151:649-655.
Hirsch, J. et al., “The reaction of some dicarbonyl sugars with aminoguanidine,”Carbohydrate Research, 1992; 232:125-130.
Horie et al., “Immunohistochemical colocalization of glyoxidation products and lipid peroxidation products in diabetic renal glomerular lesions,”J. Clin. Invest., 1997; 100:2995-3004.
IHM et al., “Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats,”Metabolism, 1999; 48:1141-1145.
Inouye et al., “ Glycated hemoglobin and lipid peroxidation in erythrocytes of diabetic patients,”Metabolism, 1999; 48:205-209.
Jain et al., “Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes,”Diabetes, 1989; 38:1539-1543.
Januszewski et al., “Role of lipids in chemical modification of proteins and development of complications in diabetes,”Biochem. Soc. Trans., 2003; 31:1413-1416.
Jenkins et al., “Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy,”Kidney Int.,2003; 64:817-828.
Kennedy et al., “Glycation, oxidation, and lipoxidation in the development of diabetic complications,”Metabolism, 1997; 46:14-21.
Kislinger et al., &#x
Figarola James L.
Rahbar Samuel
City of Hope
Henley III Raymond J.
Rothwell Figg Ernst & Manbeck
LandOfFree
Methods of lowering lipid levels in a mammal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of lowering lipid levels in a mammal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of lowering lipid levels in a mammal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800732